Growth hormone-releasing factor analogue
Tesamorelin
An approved GHRF analogue for a specific HIV-associated body-composition outcome, not a general weight-loss or anti-aging medicine.
Also known as Egrifta SV · Egrifta WR · TH9507 · GHRF analogue
01 · Evidence profile
One molecule, four evidence questions
Phase 3 trials support visceral-adipose-tissue reduction in the labeled HIV population.
The approved label characterizes IGF-1 response, exposure, and product-specific use.
The label describes neoplasm, glucose, fluid-retention, hypersensitivity, and other risks.
High for authentic Egrifta SV; no automatic transfer to other formulations.
02 · Identity
What it is
Tesamorelin is a stabilized analogue of human growth hormone-releasing factor. The approved product has a narrow labeled population and outcome.
03 · Product identity
The molecule is not the finished product.
Egrifta SV and Egrifta WR are approved, non-substitutable formulations with product-specific labeling. Tesamorelin sold or compounded outside those products is not automatically equivalent.
Egrifta SV
2024 label- Formulation
- 2 mg single-dose vial
- Route
- Subcutaneous
- Indication scope
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.
Egrifta WR
March 2025- Formulation
- 11.6 mg single-patient-use multidose vial
- Route
- Subcutaneous
- Indication scope
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.
- Egrifta SV
- Egrifta WR
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy
04 · Evidence snapshot
What the evidence can and cannot say
Controlled trials in adults with HIV-associated abdominal fat accumulation found reductions in visceral adipose tissue. The Egrifta SV and Egrifta WR labels say the products are not indicated for weight-loss management and that long-term cardiovascular safety has not been established. Their formulations are not substitutable.
Those results do not establish general fat loss, muscle gain, anti-aging benefit, athletic recovery, or equivalent outcomes from compounded products.
05 · Claim check
Three claims under the lens
“Tesamorelin reduces visceral fat in adults with HIV-associated lipodystrophy.”
Phase 3 trials and the product label support this outcome in the labeled population.
- Evidence basis
- Randomized human outcomes
- Scope
- Adults with HIV and excess abdominal fat meeting the trial and label criteria.
“Tesamorelin is an approved general weight-loss drug.”
The label specifically says it is not indicated for weight-loss management.
- Evidence basis
- Regulatory or product record
- Scope
- The current Egrifta SV and Egrifta WR labels.
“Tesamorelin is permitted for competitive athletes.”
The 2026 WADA Prohibited List names tesamorelin.
- Evidence basis
- Regulatory or product record
- Scope
- Sport governed by the World Anti-Doping Code.
06 · Safety boundary
Before this becomes personal
This is a prescription drug with population-specific benefits and meaningful monitoring requirements. No dosing, cycling, stacking, or performance-use guidance is provided.
Tesamorelin is named as a prohibited growth-hormone-releasing hormone analogue on the 2026 WADA Prohibited List.
Reviewed 2026-07-23. This status is not personal clearance to compete.Check the governing record ↗07 · Sources
Check the primary record
08 · Provenance
Review history
Updated for Egrifta SV and Egrifta WR product identity, non-substitutability, phase 3 outcomes, and the 2026 WADA list.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.